About this trial
The main objective of this study will be to compare the effects of 2 intra-articular injections of onabotulinumtoxinA with those of 1 intra-articular injection of onabotulinumtoxinA and 1 of normal saline and those of 2 intra-articular injections of normal saline on base-of-thumb pain at 6 months after the first injection.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
• Individuals aged at least 18 years;
Pain intensity of at least 30 on a self-administered 11-point pain numeric rating scale (0: no pain to 100: maximal pain);
Pain involving the base of the thumb;
X-ray evidence of trapezometacarpial osteoarthritis with at least two of the following items involving the trapezometacarpial joint: osteophytes, joint space narrowing, subchondral bone sclerosis, or subchondral cysts;
Disqualifiers
• Secondary osteoarthritis;
History of thumb surgery, inflammatory or crystal-associated rheumatic disease, or epilepsy;
Uncontrolled dysphagia, pneumonia, cardiovascular diseases, or clinical or subclinical signs of neuromuscular transmission disorders;
Contra-indication to onabotulinumtoxinA;
Trial design
Parallel
Treatments tested in this trial
OnabotulinumtoxinA
Drugintra-articular injection
Normal saline (placebo)
Drugintra-articular injection
Treatment groups
Trial outcomes
Primary outcomes
Base-of-thumb pain on a self-administered 11-point numeric rating scale
French version of the self-administered base-of-thumb pain numeric rating scale (0: no pain to 100: maximal pain)
Secondary outcomes
Base-of-thumb pain on a self-administered 11-point numeric rating scale
French version of the self-administered base-of-thumb pain numeric rating scale (0: no pain to 100: maximal pain)
Hand-specific activity limitations on the self-administered Cochin Hand Function Scale
mean change from baseline in hand-specific activity limitations in the previous 2 weeks on the self-administered Cochin Hand Function Scale (0: no limitations to 90: maximal limitations) at 6 and 12 months
patient global assessment on a self-administered 11-point numeric rating scale
mean change from baseline in patient global assessment on a self-administered 11-point numeric rating scale (0: worst possible condition to 100: best possible condition) at 6 and 12 months
health-related quality of life on the self-administered EQ-5D-5L questionnaire
mean change from baseline in health-related quality of life on the self-administered EQ-5D-5L questionnaire (0: death, 1: best quality of life) at 6 and 12 months
Sponsors and contacts
Click on the lead sponsor to view all of their trials.
Assistance Publique - Hôpitaux de Paris
Lead sponsor
URC-CIC Paris Descartes Necker Cochin
Collaborator